Werner Scheithauer
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis 38
- Oncology top 0.05%
- Colorectal Cancer Treatments and Studies 185
- Cancer Treatment and Pharmacology 122
- Pancreatic and Hepatic Oncology Research 63
- Pulmonary and Respiratory Medicine top 0.2%
- Gastric Cancer Management and Outcomes 64
- Lung Cancer Treatments and Mutations 44
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 40
- Pathology and Forensic Medicine top 0.5%
-
- Neuroendocrine Tumor Research Advances 35
Werner Scheithauer
334 papers receiving 17.8k citations
Hit Papers
Peers
Comparison fields: 5 of 147
- Hepatology 4.6k
- Oncology 14.5k
- Pulmonary and Respiratory Medicine 5.4k
- Cancer Research 2.3k
- Pathology and Forensic Medicine 1.9k
Countries citing papers authored by Werner Scheithauer
This map shows the geographic impact of Werner Scheithauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Werner Scheithauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Werner Scheithauer more than expected).
Fields of papers citing papers by Werner Scheithauer
This network shows the impact of papers produced by Werner Scheithauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Werner Scheithauer. The network helps show where Werner Scheithauer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Werner Scheithauer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 1 | |
| 3 | nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial | 2017 | 2 |
| 4 | 2012 | 237 | |
| 5 | Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Studybreakdown → | 2008 | 2275 |
| 6 | 2007 | 128 | |
| 7 | 2005 | 56 | |
| 8 | Pharmacoeconomic analysis of Capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer | 2004 | 7 |
| 9 | 2003 | 46 | |
| 10 | 2002 | 149 | |
| 11 | 2002 | 34 | |
| 12 | 1999 | 39 | |
| 13 | 1998 | 72 | |
| 14 | 1998 | 12 | |
| 15 | 1996 | 9 | |
| 16 | 1995 | 1 | |
| 17 | 1994 | 23 | |
| 18 | 1993 | 4 | |
| 19 | 1985 | 5 | |
| 20 | 1985 | 16 |
About Werner Scheithauer
Werner Scheithauer is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine, having authored 350 papers that have together received 18.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (185 papers), Cancer Treatment and Pharmacology (122 papers), Gastric Cancer Management and Outcomes (64 papers), Pancreatic and Hepatic Oncology Research (63 papers), Lung Cancer Treatments and Mutations (44 papers), Cancer Genomics and Diagnostics (40 papers), Hepatocellular Carcinoma Treatment and Prognosis (38 papers) and Neuroendocrine Tumor Research Advances (35 papers). The work is most often cited by research in Hepatology (4.6k citations), Oncology (14.5k citations) and Pulmonary and Respiratory Medicine (5.4k citations). Werner Scheithauer has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Gabriela Kornek, Arié Figer, Eduardo Díaz‐Rubio, D. Depisch, Markus Raderer, Sheryl Koski, Stephen Clarke, Leonard B. Saltz, Jim Cassidy and Thomas Gruenberger. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, European Journal of Cancer and Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.